Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)

<p>Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on Dec. 7, 2023 Olema will host an investor conference call at 8:00 a.m. ET […]</p>
<p>The post <a href="https://forextv.com/top-news/olema-oncology-to-present-new-palazestrant-clinical-data-in-combination-with-cdk4-6-inhibitors-at-the-2023-san-antonio-breast-cancer-symposium-sabcs/">Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>